BackSQZ Biotechnologies Company Overview

SQZ Biotechnologies Company Receivables

Latest receivables for SQZB: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

SQZ Biotechnologies Company Receivables History

Loading

SQZ Biotechnologies Company vs. peers: Receivables Comparison

Loading

SQZ Biotechnologies Company Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SQZ Biotechnologies Company (SQZB) FAQ

As of the most recent data (September 2023), SQZB shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SQZB's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether SQZ Biotechnologies Company is outperforming or lagging.

Tracking SQZB's receivables over time shows whether SQZ Biotechnologies Company is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has SQZ Biotechnologies Company's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

SQZ Biotechnologies Company's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.